Firehawk® Gains CFDA Approval to Offer More Specifications
Shanghai, China – 4 January, 2015 – Shanghai MicroPort Medical (Group) Co ("MicroPort") recently gained approval from China Food and Drug Administration ("CFDA") to add 24 specifications to Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®").
Firehawk® is MicroPort's third-generation drug eluting stent ("DES"), following Firebird™ Rapamycin-Eluting Coronary Stent and Firebird2™ Rapamycin-Eluting Coronary CoCr Stent, to treat coronary artery stenosis or occlusion diseases. As the world's first and only target eluting stent ("TES"), Firehawk® combines the advantages of DES and bare metal stents. Its applied targeted eluting technology allows it to achieve the same clinical efficacy as traditional DES with much lower drug dosage, and therefore greatly improving the safety of Firehawk® while maintaining its excellent efficacy.
Firehawk® was first approved for market launch by CFDA on January 23, 2014. Up to date, it has entered into 60 hospitals in 17 provinces/cities of China. With more specifications, Firehawk® will offer patients and surgeons more options to better serve their needs.
Privacy settings
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.
For more information, please see our Cookie Policy.